C. Peschel

428 total citations
13 papers, 324 citations indexed

About

C. Peschel is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, C. Peschel has authored 13 papers receiving a total of 324 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 3 papers in Surgery. Recurrent topics in C. Peschel's work include Gastric Cancer Management and Outcomes (6 papers), Colorectal Cancer Treatments and Studies (3 papers) and Lung Cancer Treatments and Mutations (3 papers). C. Peschel is often cited by papers focused on Gastric Cancer Management and Outcomes (6 papers), Colorectal Cancer Treatments and Studies (3 papers) and Lung Cancer Treatments and Mutations (3 papers). C. Peschel collaborates with scholars based in Germany, Austria and United States. C. Peschel's co-authors include Florian Lordick, Sylvie Lorenzen, Tim F. Greten, Rupert Langer, S. Al-Batran, Peter Thuss‐Patience, Markus Moehler, Dirk Arnold, Tibor Schuster and Patricia Grabowski and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.

In The Last Decade

C. Peschel

13 papers receiving 317 citations

Peers

Countries citing papers authored by C. Peschel

Since Specialization

Citations

This map shows the geographic impact of C. Peschel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Peschel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Peschel more than expected).

Fields of papers citing papers by C. Peschel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Peschel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Peschel. The network helps show where C. Peschel may publish in the future.

Co-authorship network of co-authors of C. Peschel

This figure shows the co-authorship network connecting the top 25 collaborators of C. Peschel. A scholar is included among the top collaborators of C. Peschel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Peschel. C. Peschel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie 2009 ·Annals of Oncology ·Sylvie Lorenzen, Tibor Schuster, Rainer Porschen, S. Al-Batran, Ralf‐Dieter Hofheinz, Peter Thuss‐Patience, Markus Moehler, Patricia Grabowski, Dirk Arnold, Tim F. Greten, (unknown), Nadine Röthling, C. Peschel, Rupert Langer, Florian Lordick	169
2	Combination of a Toll-like receptor 9 (TLR9) agonist, CPG 7909 (CPG) with first line taxane/platinum improves response rate in late stage non-small-cell lung cancer (NSCLC) 2005 ·mediaTUM (Technical University of Munich) ·C. Manegold, J. Mezger, C. Peschel, (unknown), (unknown), Mohammed Al-Adhami, Tess Schmalbach	2
3	Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer 2005 ·British Journal of Cancer ·Florian Lordick, Sylvie Lorenzen, J. Stollfuß, Ursula Vehling‐Kaiser, Frank Kullmann, Marcus Hentrich, (unknown), (unknown), (unknown), Michael Hennig, (unknown), Rainer Bredenkamp, Justus Duyster, C. Peschel	69
4	Individualized indication for neoadjuvant treatment based on metabolic response Assessed by 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in adenocarcinoma of the esophago-gastric junction (AEG) 2005 ·Journal of Clinical Oncology ·Florian Lordick, Katja Ott, Wolfgang Weber, H. J. Stein, Karl‐Friedrich Becker, Hinrich Wieder, (unknown), (unknown), C. Peschel, Markus Schwaiger, J. R. Siewert	3
5	Primary CNS Lymphoma - High-Dose-Chemotherapy with Autologous PBSCT and Hyperfractionated Radiotherapy as First-Line-Therapy - Results of a Multicenter Phase II Study. 2005 ·Blood ·Gerald Illerhaus, Reinhard Marks, (unknown), C. Peschel, Norbert Frickhofen, Roland Guttenberger, Thomas Kubin, Christoph B. Ostertag, Jürgen Finke	5
6	Adjuvant therapy for colon cancer 2004 ·DMW - Deutsche Medizinische Wochenschrift ·Florian Lordick, (unknown), H. J. Stein, C. Peschel, J. R. Siewert	2
7	Individualized neoadjuvant treatment strategy in adenocarcinoma of the esophago-gastric junction (AEG): Interim report on the MUNICON trial 2004 ·Journal of Clinical Oncology ·Florian Lordick, Wolfgang Weber, H. J. Stein, (unknown), (unknown), Michael Hennig, Katja Ott, C. Peschel, Markus Schwaiger, J. R. Siewert	3
8	A prospective Multicenter study of the BMPD regimen with or without radiotherapy for primary CNS lymphoma. 2003 ·mediaTUM (Technical University of Munich) ·Agnieszka Korfel, Peter Martus, (unknown), DK Hossfeld, Heinz Kirchen, (unknown), (unknown), Josef Birkmann, C. Peschel, R. Pasold, Lutz Fischer, Kristoph Jahnke, E. Thiel	1
9	Report of a male patient with brain metastases from breast cancer 2003 ·The Breast ·Carsten Nieder, Philipp J. Jost, Anca-Ligia Grosu, C. Peschel, M. Molls	4
10	215 A randomized, multinational phase III study in first line metastatic and locally recurrent gastric cancer (MGC): CPT-11 plus 5-fluorouracil (5-FU)/leucovorin (LV) versus cisplatinum (CDDP) plus 5-FU 2003 ·European Journal of Cancer Supplements ·Magdolna Dank, J. Załuski, Carlo Barone, Vahur Valvere, (unknown), C. Peschel, Erdem Göker, M. Wenczl, Sylvie Assadourian, R. Bugat	4
11	Adjunctive interferon-alpha-2c in stage IIIB/IV small-cell lung cancer: a phase III trial 1997 ·European Respiratory Journal ·C. Prior, (unknown), W. Oberaigner, Erin L. Schenk, Florian Kummer, K Aigner, H. Hausmaninger, C. Peschel, H. Huber	18
12	Preliminary results of stem cell mobilization in chronic myeloid leukemia with a moderate intensity chemotherapy regimen and G-CSF or G-CSF plus IL-3. 1996 ·PubMed ·(unknown), Andreas Neubauer, Karin Kolbe, Folker Schneller, Christoph Busemann, E. Schleiermacher, C. Peschel, W. Siegert, Christian G. Huber, D. Huhn	2
13	Plasma levels of IL-1, TNF alpha, IL-6, IL-8, G-CSF, and IL1-RA during febrile neutropenia: Results of a prospective study in patients undergoing chemotherapy for acute myelogenous leukemia 1995 ·Annals of Hematology ·(unknown), Martin Schüler, Karin Kolbe, C. Peschel, Christoph Huber, (unknown), W. E. Aulitzky	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact